|
In the pharmaceutical outsourcing markets, contract manufacturing of APIs and finished drugs are very important areas. The latest studies have shown that the contract pharmaceutical production will show a moderate - strong growth. In 2011, total revenue of global pharmaceutical glutathione contract manufacturing reached nearly $ 218 billion. It is expected that in 2016 this data will reach nearly $ 361 billion with the compound annual growth rate of 10.6%. Pharmaceutical contract manufacturing can be divided into four areas: non prescription drugs and nutritional health products, contract manufacturing, contract manufacturing of bulk drugs and formulations, contract research and contract packaging. According to analysis, in 2011 the global bulk drugs and formulations contract manufacturing revenue is $ 53.4 billion. It is expected that this market will grow at a CAGR of 10.1 percent growth to reach $ 86.3 billion in 2016. If a specific analysis, the field of contract manufacturing of bulk drugs is expected to show a moderate growth. In 2010, the global pharmaceutical raw materials market size reached $ 101 billion. Monopoly market (ie pharmaceutical companies in this market, the total value of the internal organization of production, pharmaceutical raw materials for their own needs) accounted for 61.4% of the share of bulk drugs market; commodity bulk drugs market (sales by a third party API) accounted for the remaining 38.6% share (about $ 39 billion). Commodity bulk drugs, the global commodity bulk drugs market almost supplied to the generics market of pharmaceutical raw materials and supplies to the brand-name drugs (including study drug) markets bulk drugs have equal shares. 2010, in the global commodity bulk drugs on the market for generic drugs, pharmaceutical raw materials account for about 48.7 percent (about $ 19 billion), and for brand-name drugs accounted for the remaining 51.3% of pharmaceutical raw materials (about $ 20 billion). In the next five years, global commodity bulk drugs market for generic drugs and brand drugs is expected grow by an average rate of 5.1%. It is from $ 39 billion in 2010 to $ 50 billion in 2015. However, the bulk irinotecan drugs demand for generic drugs will be greater than the growth of bulk drugs for brand-name drugs. It is expected that generic bulk drugs market will grow at a 7.3 percent annual growth rate. The size of market in 2015 will reach $ 27 billion. Commodity raw materials market for the brand drug is expected to grow by only 2.8% and the size of market in 2015 will reach $ 23 billion. This growth rate differences will make the commodity bulk drugs for generics in the market occupied by the share increased from 49.7% in 2010 to 54% in 2015. It will make the commodity bulk drugs for brand-name drugs on the market occupied by the share reduced from 51.3% in 2010 to 46% in 2015.Source:http://www.cospcn.com
Related Articles -
pharmaceutical raw materials, Glutathione, Resveratrol, Chia seed,
|
